G1 Therapeutics, Inc. (GTHX): Price and Financial Metrics


G1 Therapeutics, Inc. (GTHX): $7.91

-0.19 (-2.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GTHX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GTHX POWR Grades

  • Growth is the dimension where GTHX ranks best; there it ranks ahead of 82.12% of US stocks.
  • The strongest trend for GTHX is in Value, which has been heading up over the past 177 days.
  • GTHX's current lowest rank is in the Stability metric (where it is better than 1.35% of US stocks).

GTHX Stock Summary

  • With a price/sales ratio of 7.42, G1 THERAPEUTICS INC has a higher such ratio than 83.38% of stocks in our set.
  • With a year-over-year growth in debt of 121%, G1 THERAPEUTICS INC's debt growth rate surpasses 89.51% of about US stocks.
  • The volatility of G1 THERAPEUTICS INC's share price is greater than that of 91.99% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to G1 THERAPEUTICS INC, a group of peers worth examining would be VYNE, SMTC, TTOO, ACVA, and FORM.
  • Visit GTHX's SEC page to see the company's official filings. To visit the company's web site, go to www.g1therapeutics.com.

GTHX Valuation Summary

  • In comparison to the median Healthcare stock, GTHX's price/sales ratio is 33.33% higher, now standing at 6.8.
  • GTHX's price/sales ratio has moved NA NA over the prior 69 months.

Below are key valuation metrics over time for GTHX.

Stock Date P/S P/B P/E EV/EBIT
GTHX 2023-01-30 6.8 6.9 -2.1 -2.2
GTHX 2023-01-27 6.1 6.3 -1.9 -1.9
GTHX 2023-01-26 6.0 6.1 -1.8 -1.9
GTHX 2023-01-25 6.2 6.3 -1.9 -2.0
GTHX 2023-01-24 6.3 6.4 -1.9 -2.0
GTHX 2023-01-23 6.1 6.2 -1.9 -1.9

GTHX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GTHX has a Quality Grade of D, ranking ahead of 22.6% of graded US stocks.
  • GTHX's asset turnover comes in at 0.239 -- ranking 181st of 681 Pharmaceutical Products stocks.
  • NVAX, SRRA, and OCX are the stocks whose asset turnover ratios are most correlated with GTHX.

The table below shows GTHX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.239 0.984 -3.150
2021-03-31 0.219 0.996 -3.451
2020-12-31 0.182 1.000 -5.667
2020-09-30 0.101 1.000 -9.018
2020-06-30 0.000 NA -13.386
2020-03-31 0.000 NA -148.700

GTHX Price Target

For more insight on analysts targets of GTHX, see our GTHX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.86 Average Broker Recommendation 1.44 (Moderate Buy)

GTHX Stock Price Chart Interactive Chart >

Price chart for GTHX

GTHX Price/Volume Stats

Current price $7.91 52-week high $17.49
Prev. close $8.10 52-week low $3.84
Day low $7.75 Volume 917,400
Day high $8.10 Avg. volume 1,005,548
50-day MA $6.20 Dividend yield N/A
200-day MA $8.30 Market Cap 339.43M

G1 Therapeutics, Inc. (GTHX) Company Bio


G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. The company was founded in 2008 and is based in Research Triangle Park, North Carolina.


GTHX Latest News Stream


Event/Time News Detail
Loading, please wait...

GTHX Latest Social Stream


Loading social stream, please wait...

View Full GTHX Social Stream

Latest GTHX News From Around the Web

Below are the latest news stories about G1 THERAPEUTICS INC that investors may wish to consider to help them evaluate GTHX as an investment opportunity.

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,800 shares of G1’s common stock and 1,400 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to th

Yahoo | February 1, 2023

G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference. The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeu

Yahoo | January 11, 2023

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

- Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion - - Five Clinical Trials with Data Readouts in 2023 Will Evaluate Trilaciclib On-Target Effects of Myeloprotection and Enhanced Immune Function with Potential for Improved Efficacy Outcomes (Progression Free (PFS) and Overall Survival (OS)) - - Trilaciclib’s Potential Synergistic Effects with Chemotherapy, Antibody Dru

Yahoo | January 9, 2023

G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial

G1 Therapeutics Inc (NASDAQ: GTHX) provided an initial update on the PRESERVE 3 Phase 2 study of first-line platinum-based chemotherapy and maintenance therapy with avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Additional safety and efficacy data, including the primary endpoint of progression-free survival (PFS), are anticipated in the middle of 2023. The confirmed objective response rate (

Yahoo | January 4, 2023

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided an initial update on PRESERVE 3, an ongoing Phase 2, randomized, open-label study of first-line platinum-based chemotherapy and maintenance therapy with the immune checkpoint inhibitor, avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Additio

Yahoo | January 4, 2023

Read More 'GTHX' Stories Here

GTHX Price Returns

1-mo 52.41%
3-mo -0.88%
6-mo -33.25%
1-year -19.04%
3-year -61.28%
5-year -63.26%
YTD 45.67%
2022 -46.82%
2021 -43.25%
2020 -31.93%
2019 38.02%
2018 -3.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7604 seconds.